Post-earnings recap
Reported
Fri, Aug 11, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Soleno Therapeutics reported a loss per share of $-0.06, with no revenue figures disclosed. The stock fell by 1.23% following the earnings report, indicating investor caution due to the lack of financial metrics and guidance. The absence of specific revenue updates may lead to uncertainty among investors about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.06 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management's commentary reflected a neutral stance on current operations. There were no significant updates or changes to their strategic direction.
Management did not provide specific updates on revenue expectations.
The company remains focused on its ongoing projects and initiatives.